PRACTICE

Prevent Rheumatoid Arthritis in Practice

 Coordinatore KAROLINSKA INSTITUTET 

Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie.

 Nazionalità Coordinatore Sweden [SE]
 Totale costo 156˙000 €
 EC contributo 144˙300 €
 Programma FP7-IDEAS-ERC
Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
 Code Call ERC-2011-PoC
 Funding Scheme CSA-SA(POC)
 Anno di inizio 2012
 Periodo (anno-mese-giorno) 2012-09-01   -   2013-08-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    KAROLINSKA INSTITUTET

 Organization address address: Nobels Vag 5
city: STOCKHOLM
postcode: 17177

contact info
Titolo: Ms.
Nome: Caroline
Cognome: Hamilton
Email: send email
Telefono: +46 8 51775959

SE (STOCKHOLM) hostInstitution 144˙300.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

inducing    erc    autoimmune    vaccination    animal    ra    immune    arthritis    human    idea    actions    investors    ipr    prominent    specificity    disease    immunity   

 Obiettivo del progetto (Objective)

'The idea is to develop vaccines and companion diagnostics for treatment of rheumatoid arthritis (RA). The idea is built on (i) knowledge that the immune systems harbors a capacity for specific reregulation of its actions, both in increasing its actions (e.g. existing vaccination against polio, measles etc.) and in decreasing its actions (“vaccinations” against autoimmune diseases, which has so far been executed successfully in animal models where enough is known about specificity for disease-inducing immunity); (ii) an insight that a major hurdle for development of “specific immunotherapy” (vaccination) in human autoimmune disease is a lack of enough understanding of the specificity of disease-inducing immune reactions in the human conditions; (iii) very significant progress that is currently being made within my ERC-funded project and in other groups concerning specificity of arthritis-inducing immunity in subsets of RA where these subsets are defined by the combined actions of genes, environment and immunity; most importantly, we have been able to define the specific structures (MHC classII-peptide complexes) that are recognized by potentially disease-inducing Tcells in RA. This has been a major lacking feature for the development of specific immunotherapies in this disease.

We will use the ERC PoC funds to improve our understanding of the industry landscape and regulatory requirements, secure strategic collaborations, broaden and strengthen our patent portfolio, set-up a limited IPR based company set up and develop an attractive “investors package”. By the end of the period we will seek financing from private investors. Our team consists of the ERC grant holder (Lars Klareskog), a prominent animal arthritis experimentalist (Rikard Holmdahl), a prominent cell immunologist (Vivianne Malmström), and two colleagues with a large experience in establishing start-ups, IPR management and venture capital funding.'

Altri progetti dello stesso programma (FP7-IDEAS-ERC)

SYSTEMSHOX.CH (2009)

A System Approach to Hox Genes Regulation in Vertebrates

Read More  

HPFLUDY (2011)

The h-Principle for Fluid Dynamics

Read More  

EXQUISITE (2014)

External Quantum Control of Photonic Semiconductor Nanostructures

Read More